Recent cardiovascular outcome trials in patients with type 2 diabetes mellitus (T2DM) [1–3], and dedicated heart failure (HF) trials in patients with HF and reduced ejection fraction (HFrEF) with or without T2DM [4–6] have demonstrated a consistently significant reduction in hospitalization for HF with SGLT2 inhibitor treatment versus placebo. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.